Antibody Therapy

Anti-ICAM-1 Blockade Does Not Improve Early Graft Function

Published in Vaccine Weekly, July 5th, 2000

Anti-ICAM-1 blockade did not improve early graft function in a rat liver transplantation model, according to a recent study.

"The present in vivo study investigated the impact of a monoclonal antibody (MAb) directed against the intercellular adhesion molecule-1 (ICAM-1) on initial microvascular reperfusion injury after liver transplantation," wrote M. Rentsch and colleagues, Klinikum University Regensburg, Germany. "Orthotopic, syngeneic liver transplantation including arterial reconstruction was performed in male Lewis rats after 24 hour graft storage in University of Wisconsin (UW) solution at 4(degree)C."

Rentsch et al. published their study in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-07-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry